Clinical Trials Logo
  1. Home
  2. Type 1 Diabetes
  3. NCT04711382
  4. Details
NCT04711382 Clinical Trial

The Use of Faster Acting Aspart in Type 1 Diabetes Patients

Type 1 Diabetes Clinical Trial

Official title:
The Use of Faster Acting Aspart in Type 1 Diabetes Patients: Multi-centre Real-world Experience

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04711382
Other study ID # Fiasp real-world data
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 29, 2018
Est. completion date January 1, 2021

Study information
Verified date December 2020
Source University Hospital, Antwerp
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from traditional mealtime insulin to Fiasp in a "real-world" clinical practice setting in people with type 1 diabetes in Belgium.

Description:

The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12 months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range (T<70 and T<54 mg/dl) and time above range (T>180 and T>250 mg/dl). Retrospective analysis Two-center study

Recruitment information / eligibility
Status Completed
Enrollment 438
Est. completion date January 1, 2021
Est. primary completion date December 14, 2020
Accepts healthy volunteers No
Gender All
Age group 16 Years to 100 Years
Eligibility Inclusion Criteria: - Type 1 diabetes patients - Duration of diabetes > 2 years - Using CGM for > 6 months Exclusion Criteria: - Using SMBG - Pregnancy - Using glucocorticoids or immunosuppressive agents - Active oncological problem

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Belgium Antwerp University Hospital Edegem Antwerp

Sponsors (2)
Lead Sponsor Collaborator
University Hospital, Antwerp Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary Time in Range Time in target range at 12 months 12 months
Secondary Time in Range Time in target range at 6 months 6 months
Secondary Change in HbA1c Change in HbA1c 6 months & 12 months
Secondary Change in weight Change in weight 6 months & 12 months
Secondary Change in insulin doses Change in insulin doses 6 months & 12 months
Secondary Time below range Change in time below range 6 months & 12 months
Secondary Time above range Change in time above range 6 months & 12 months
Secondary Coefficient of variation Change in coefficient of variation 6 months & 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany